$CMND News

Clearmind Medicine Files Japanese Patent Application For Its Proprietary Compositions Comprising 5-Methoxy-2-Aminoindan To Treat Depression

Clearmind Medicine Announces Johns Hopkins Approval For CMND-100 Phase 1/2 Clinical Trial

Clearmind Medicine Inks Research Agreement With Yissum Research Development To Evaluate Metabolic Efficacy Of MEAI Both In Combination With, Maintenance Therapy Following Tirzepatide Treatment In Diet-Induced Obese Mice

Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder

Clearmind Medicine Announces Dosing Of Two Additional Patients In Fourth Group Of Its Phase I/IIa Clinical Study Of CMND-100 To Treat Moderate To Severe Alcohol Use Disorder

Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial

Clearmind Medicine Shares New CMND-100 Clinical Trial Data Ahead Of June Investor Webinar

Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD

Clearmind Medicine Files European Patent Application For Innovative Psychedelic Compounds Targeting The Treatment Of Post-Traumatic Stress Disorder And Other Mental Health Disorders

Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation

Clearmind Medicine Evaluates Lead Candidate, CMND-100 (MEAI), For Eligibility For FDA's Breakthrough Therapy Designation

Why Is Clearmind Medicine Stock Sliding On Wednesday?

Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

Why Is Clearmind Stock Rising Monday?

Clearmind Medicine shares are trading higher after the company announced that CMND-100 met the primary endpoint in its FDA-approved Phase I/IIa clinical trial.

Clearmind Medicine shares are trading higher after the company announced that CMND-100 met the primary endpoint in its FDA-approved Phase I/IIa clinical trial.

Clearmind Medicine Says CMND-100, Proprietary Non-Hallucinogenic MEAI-Based Oral Drug Candidate, For Treatment Of AUD Met Primary Endpoint In Its FDA-Approved Phase I/IIa Clinical Trial

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial